Chromosomal changes associated with clinical outcome in lymph node-negative breast cancer

Cancer Genetics and Cytogenetics

Volumn 172, Issue 2, 2007, Pages 139-146

  Karlsson, Elin ^a   Danielsson, Anna ^a   Delle, Ulla ^a   Olsson, Björn ^b   Karlsson, Per ^c   Helou, Khalil ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b UNIVERSITY OF SKÖVDE   (Sweden)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

DNA;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER PATIENT; CANCER SURVIVAL; CHROMOSOME 12Q; CHROMOSOME 14Q; CHROMOSOME 17P; CHROMOSOME 18P; CHROMOSOME 5Q; CHROMOSOME 6Q; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; CHROMOSOME LOSS; CHROMOSOME XQ; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; LYMPH NODE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; TUMOR RECURRENCE;

EID: 33846010199     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cancergencyto.2006.09.019     Document Type: Article

References (40)

1. Berry D.A., Cronin K.A., Plevritis S.K., Fryback D.G., Clarke L., Zelen M., Mandelblatt J.S., Yakovlev A.Y., Habbema J.D., and Feuer E.J. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 353 (2005) 1784-1792
2. Ries LAG EM, Kosary CL, Hankey BF, Miller BA, Clegg L, Mariotto A, Feuer EJ, Edward BK, editors. SEER Cancer Statistics Review, 1975-2002. Available at: http://www.seercancergov/csr/1975_2002 based on November 2004 SEER data submission, posted to the SEER web site 2005.
3. Goldhirsch A., Glick J.H., Gelber R.D., Coates A.S., Thurlimann B., and Senn H.J. Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 16 (2005) 1569-1583
4. Michaelson J.S., Silverstein M., Sgroi D., Cheongsiatmoy J.A., Taghian A., Powell S., Hughes K., Comegno A., Tanabe K.K., and Smith B. The effect of tumor size and lymph node status on breast carcinoma lethality. Cancer 98 (2003) 2133-2143
5. Cingoz S., Altungoz O., Canda T., Saydam S., Aksakoglu G., and Sakizli M. DNA copy number changes detected by comparative genomic hybridization and their association with clinicopathologic parameters in breast tumors. Cancer Genet Cytogenet 145 (2003) 108-114
6. Climent J., Martinez-Climent J.A., Blesa D., Garcia-Barchino M.J., Saez R., Sanchez-Izquierdo D., Azagra P., Lluch A., and Garcia-Conde J. Genomic loss of 18p predicts an adverse clinical outcome in patients with high-risk breast cancer. Clin Cancer Res 8 (2002) 3863-3869
7. Fung L.F., Wong N., Tang N., Lau A., Wong V., Pang C.P., Suen M., King W., and Johnson P.J. Genetic imbalances in pT2 breast cancers of southern Chinese women. Cancer Genet Cytogenet 124 (2001) 56-61
8. Hislop R.G., Pratt N., Stocks S.C., Steel C.M., Sales M., Goudie D., Robertson A., and Thompson A.M. Karyotypic aberrations of chromosomes 16 and 17 are related to survival in patients with breast cancer. Br J Surg 89 (2002) 1581-1586
9. Jones C., Ford E., Gillett C., Ryder K., Merrett S., Reis-Filho J.S., Fulford L.G., Hanby A., and Lakhani S.R. Molecular cytogenetic identification of subgroups of grade III invasive ductal breast carcinomas with different clinical outcomes. Clin Cancer Res 10 (2004) 5988-5997
10. Rennstam K., Ahlstedt-Soini M., Baldetorp B., Bendahl P.O., Borg A., Karhu R., Tanner M., Tirkkonen M., and Isola J. Patterns of chromosomal imbalances defines subgroups of breast cancer with distinct clinical features and prognosis. A study of 305 tumors by comparative genomic hybridization. Cancer Res 63 (2003) 8861-8868
11. Robanus-Maandag E.C., Bosch C.A., Kristel P.M., Hart A.A., Faneyte I.F., Nederlof P.M., Peterse J.L., and van de Vijver M.J. Association of C-MYC amplification with progression from the in situ to the invasive stage in C-MYC-amplified breast carcinomas. J Pathol 201 (2003) 75-82
12. Seute A., Sinn H.P., Schlenk R.F., Emig R., Wallwiener D., Grischke E.M., Hohaus S., Dohner H., Haas R., and Bentz M. Clinical relevance of genomic aberrations in homogeneously treated high-risk stage II/III breast cancer patients. Int J Cancer 93 (2001) 80-84
13. Zudaire I., Odero M.D., Caballero C., Valenti C., Martinez-Penuela J.M., Isola J., and Calasanz M.J. Genomic imbalances detected by comparative genomic hybridization are prognostic markers in invasive ductal breast carcinomas. Histopathology 40 (2002) 547-555
14. Hermsen M.A., Baak J.P., Meijer G.A., Weiss J.M., Walboomers J.W., Snijders P.J., and van Diest P.J. Genetic analysis of 53 lymph node-negative breast carcinomas by CGH and relation to clinical, pathological, morphometric, and DNA cytometric prognostic factors. J Pathol 186 (1998) 356-362
15. Janssen E.A., Baak J.P., Guervos M.A., van Diest P.J., Jiwa M., and Hermsen M.A. In lymph node-negative invasive breast carcinomas, specific chromosomal aberrations are strongly associated with high mitotic activity and predict outcome more accurately than grade, tumour diameter, and oestrogen receptor. J Pathol 201 (2003) 555-561
16. Dellas A., Torhorst J., Schultheiss E., Mihatsch M.J., and Moch H. DNA sequence losses on chromosomes 11p and 18q are associated with clinical outcome in lymph node-negative ductal breast cancer. Clin Cancer Res 8 (2002) 1210-1216
17. Isola J.J., Kallioniemi O.P., Chu L.W., Fuqua S.A., Hilsenbeck S.G., Osborne C.K., and Waldman F.M. Genetic aberrations detected by comparative genomic hybridization predict outcome in node-negative breast cancer. Am J Pathol 147 (1995) 905-911
18. Sobin L.H., and Wittekind C. TNM Classification of Malignant Tumours. 6th edition (2002), John Wiley & Sons, Hoboken, NJ
19. Kallioniemi A., Kallioniemi O.P., Sudar D., Rutovitz D., Gray J.W., Waldman F., and Pinkel D. Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors. Science 258 (1992) 818-821
20. Kallioniemi O.P., Kallioniemi A., Piper J., Isola J., Waldman F.M., Gray J.W., and Pinkel D. Optimizing comparative genomic hybridization for analysis of DNA sequence copy number changes in solid tumors. Genes Chromosomes Cancer 10 (1994) 231-243
21. Osterberg L., Levan K., Partheen K., Helou K., and Horvath G. Cytogenetic analysis of carboplatin resistance in early-stage epithelial ovarian carcinoma. Cancer Genet Cytogenet 163 (2005) 144-150
22. Struski S., Doco-Fenzy M., and Cornillet-Lefebvre P. Compilation of published comparative genomic hybridization studies. Cancer Genet Cytogenet 135 (2002) 63-90
23. Loveday R.L., Greenman J., Simcox D.L., Speirs V., Drew P.J., Monson J.R., and Kerin M.J. Genetic changes in breast cancer detected by comparative genomic hybridisation. Int J Cancer 86 (2000) 494-500
24. Benoy I.H., Salgado R., Van Dam P., Geboers K., Van Marck E., Scharpe S., Vermeulen P.B., and Dirix L.Y. Increased serum interleukin-8 in patients with early and metastatic breast cancer correlates with early dissemination and survival. Clin Cancer Res 10 (2004) 7157-7162
25. Allen J.D., and Schinkel A.H. Multidrug resistance and pharmacological protection mediated by the breast cancer resistance protein (BCRP/ABCG2). Mol Cancer Ther 1 (2002) 427-434
26. Urquidi V., Sloan D., Kawai K., Agarwal D., Woodman A.C., Tarin D., and Goodison S. Contrasting expression of thrombospondin-1 and osteopontin correlates with absence or presence of metastatic phenotype in an isogenic model of spontaneous human breast cancer metastasis. Clin Cancer Res 8 (2002) 61-74
27. Samady L., Faulkes D.J., Budhram-Mahadeo V., Ndisang D., Potter E., Brabant G., and Latchman D.S. The Brn-3b POU family transcription factor represses plakoglobin gene expression in human breast cancer cells. Int J Cancer 118 (2006) 869-878
28. Tirkkonen M., Tanner M., Karhu R., Kallioniemi A., Isola J., and Kallioniemi O.P. Molecular cytogenetics of primary breast cancer by CGH. Genes Chromosomes Cancer 21 (1998) 177-184
29. Partheen K., Levan K., Osterberg L., Helou K., and Horvath G. Analysis of cytogenetic alterations in stage III serous ovarian adenocarcinoma reveals a heterogeneous group regarding survival, surgical outcome, and substage. Genes Chromosomes Cancer 40 (2004) 342-348
30. Prokopchuk O., Liu Y., Henne-Bruns D., and Kornmann M. Interleukin-4 enhances proliferation of human pancreatic cancer cells: evidence for autocrine and paracrine actions. Br J Cancer 92 (2005) 921-928
31. Watkins G., Douglas-Jones A., Bryce R., Mansel R.E., and Jiang W.G. Increased levels of SPARC (osteonectin) in human breast cancer tissues and its association with clinical outcomes. Prostaglandins Leukot Essent Fatty Acids 72 (2005) 267-272
32. Wadhwa R., Takano S., Kaur K., Deocaris C.C., Pereira-Smith O.M., Reddel R.R., and Kaul S.C. Upregulation of mortalin/mthsp70/Grp75 contributes to human carcinogenesis. Int J Cancer 118 (2006) 2973-2980
33. Turbin D.A., Cheang M.C., Bajdik C.D., Gelmon K.A., Yorida E., De Luca A., Nielsen T.O., Huntsman D.G., and Gilks C.B. MDM2 protein expression is a negative prognostic marker in breast carcinoma. Mod Pathol 19 (2006) 69-74
34. Somai S., Gompel A., Rostene W., and Forgez P. Neurotensin counteracts apoptosis in breast cancer cells. Biochem Biophys Res Commun 295 (2002) 482-488
35. Langelotz C., Schmid P., Jakob C., Heider U., Wernecke K.D., Possinger K., and Sezer O. Expression of high-mobility-group-protein HMGI-C mRNA in the peripheral blood is an independent poor prognostic indicator for survival in metastatic breast cancer. Br J Cancer 88 (2003) 1406-1410
36. Louhimo J., Carpelan-Holmstrom M., Alfthan H., Stenman U.H., Jarvinen H.J., and Haglund C. Serum HCG beta, CA 72-4 and CEA are independent prognostic factors in colorectal cancer. Int J Cancer 101 (2002) 545-548
37. Reis-Filho J.S., Simpson P.T., Gale T., and Lakhani S.R. The molecular genetics of breast cancer: the contribution of comparative genomic hybridization. Pathol Res Pract 201 (2005) 713-725
38. Downing S.R., Russell P.J., and Jackson P. Alterations of p53 are common in early stage prostate cancer. Can J Urol 10 (2003) 1924-1933
39. Kominsky S.L., Argani P., Korz D., Evron E., Raman V., Garrett E., Rein A., Sauter G., Kallioniemi O.P., and Sukumar S. Loss of the tight junction protein claudin-7 correlates with histological grade in both ductal carcinoma in situ and invasive ductal carcinoma of the breast. Oncogene 22 (2003) 2021-2033
40. Klebig C., Seitz S., Arnold W., Deutschmann N., Pacyna-Gengelbach M., Scherneck S., and Petersen I. Characterization of {gamma}-aminobutyric acid type A receptor-associated protein, a novel tumor suppressor, showing reduced expression in breast cancer. Cancer Res 65 (2005) 394-400